Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

In the phase III PALETTE trial, pazopanib improved progression-free survival (PFS) compared with placebo in patients with advanced/metastatic soft tissue sarcomas (mSTS) who had received prior chemotherapy. We used a multistate model to estimate expected PFS, overall survival (OS), lifetime STS trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Amdahl, Jordan, Manson, Stephanie C., Isbell, Robert, Chit, Ayman, Diaz, Jose, Lewis, Lily, Delea, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082932/
https://www.ncbi.nlm.nih.gov/pubmed/25024640
http://dx.doi.org/10.1155/2014/481071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082932/
https://www.ncbi.nlm.nih.gov/pubmed/25024640
http://dx.doi.org/10.1155/2014/481071

Ejemplares similares